Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.
Johannes Schetelig(University Hospital Carl Gustav Carus), Gerhard Ehninger(University Hospital Carl Gustav Carus), Christian Thiede(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Alexander Kiani(Bayreuth Medical Center), W. Siegert(University of Göttingen), Karin Kolbe(Johannes Gutenberg University Mainz), Gaby Geissler(Klinikum Chemnitz), Kerstin Schaefer‐Eckart(Klinikum Arnsberg), Uwe Platzbecker(National Center for Tumor Diseases), Martin Kaufmann(Robert Bosch Hospital), Matthias Zeis(Asklepios Klinik St. Georg), Rainer Schwerdtfeger(Deutsche Klinik für Diagnostik), Matthias W. Haenel(Klinikum Chemnitz)
Cited by 2
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k